Market Access A year of major M&A ahead? The previous few years have seen a slowdown in M&A across the industry, as companies take a cautious approach to expansion.
News Bayer trial combines two top drugs for kidney disease Data from the CONFIDENCE trial shows the value of combining Bayer's Kerendia with an SGLT2 inhibitor to treat chronic kidney disease in diabetics.